ClinicalTrials.gg
RecruitingNCT07219589Updated May 4, 2026

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

A Phase 1 interventional study of HM17321 and Placebo of HM17321 in Obesity and Obese, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321, a urocortine 2 (UCN2) analog, administered by subcutaneous (SC) injection in healthy and obese participants.

The study consists of two parts: Part A (Single Ascending Dose) and Part B (Multiple Ascending Dose), with approximately 90 participants to be enrolled in total.

In Part A, approximately 40 healthy participants with a body mass index (BMI) of ≥20 kg/m² and ≤27 kg/m² will be enrolled across 5 sequential dose cohorts. Each cohort will consist of approximately 8 participants randomized in a 6:2 ratio to receive a single SC dose of HM17321 or placebo. A sentinel dosing strategy will be applied in each cohort to ensure participant safety, with initial safety data reviewed prior to dosing the remainder of the cohort. Dose escalation decisions will be made by a Safety Review Committee (SRC) based on safety, tolerability, and available PK data. Part A will include a screening period of up to 28 days, a 5-day inpatient stay with single SC dosing, and an outpatient follow-up period through Day 29, with an overall study duration of approximately 8 weeks per participant.

In Part B, approximately 50 healthy obese participants with a BMI of ≥30 kg/m² and ≤45 kg/m² will be enrolled across 5 sequential dose cohorts. Each cohort will consist of approximately 10 participants randomized in an 8:2 ratio to receive once-weekly SC doses of HM17321 or placebo over a 12-week treatment period. Dose escalation will be guided by SRC review of safety, tolerability, and PK data at predefined time points. Part B will include a screening period of up to 45 days, a 12-week treatment period with once-weekly SC dosing, and a 4-week follow-up period through Day 113, with an overall study duration of approximately 22 weeks per participant.

02

Conditions studied

  • Obesity
  • Obese

Browse trials for

Keywords

  • Obese
  • Obesity
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 90 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years.
  • Part A: Healthy participants with ≥20 kg/m² and ≤27 kg/m² at screening.
  • Part B: Healthy obese participants with BMI ≥30 kg/m² and ≤45 kg/m² at screening.
  • Stable body weight (\<5% change) in the past 3 months.
  • Able and willing to provide written .
  • Male participants must use or remain abstinent from women of .
  • Female participants must not be pregnant or breastfeeding and use highly effective contraception if of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • History of any bariatric procedure.
  • Uncontrolled thyroid disease (TSH >6.0 or \<0.4 mIU/L).
  • Abnormal liver function or liver disease

    • Part A: or AST ≥ , or total ≥ ULN
    • Part B: ALT or AST >2× ULN, or total bilirubin >1.5× ULN
  • Abnormal pancreatic function

    • Part A: amylase or lipase ≥ ULN
    • Part B: amylase or lipase >3× ULN
  • Clinically significant cardiovascular disorders (e.g., myocardial infarction, congestive heart failure, long syndrome).
  • Abnormal renal function ( \<60 mL/min/1.73 m²).
  • Positive test for , , or at screening.
  • Women who are pregnant, planning to become pregnant, or breastfeeding.
  • History of drug or alcohol abuse within defined timeframes (e.g., alcohol >14 standard units/week in past year, or positive drug screen).
  • Use of any product within 30 days or 5 half-lives (whichever is longer) prior to screening.
  • Additional Exclusion Criteria for Part B

    • ≥6.5% or a history of diabetes mellitus (type 1 or type 2).
    • Obesity induced by other endocrine disorders (e.g., Cushing syndrome).
    • Use of weight control treatments (e.g., GLP-1 receptor agonists or other anti-obesity medications) and antihypertensive medications within 3 months prior to screening.
    • Use of any lipid-lowering medications, unless on a stable dose for at least 3 months prior to screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    HM17321

    Drug: HM17321

  • Placebo comparator
    Placebo

    Drug: Placebo of HM17321

Interventions

  • DrugHM17321

    Participants will receive a single or multiple subcutaneous injections of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.

  • DrugPlacebo of HM17321

    Participants will receive a single or multiple subcutaneous injections of a matching placebo solution in prefilled syringes. The placebo does not contain any active ingredients.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) Following Single and Multiple Subcutaneous Doses of HM17321

    Number, type, and severity of treatment-emergent adverse events, including changes in vital signs, electrocardiograms, clinical laboratory tests, and immunogenicity assessments following administration of HM17321 or placebo

    Time frame: Up to Day 29 (Part A); Up to Day 113 (Part B)

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of HM17321

    Maximum observed plasma concentration of HM17321 following single and multiple subcutaneous doses.

    Time frame: Up to Day 29 (Part A); Up to Day 113 (Part B)

  2. Time to Maximum Plasma Concentration (Tmax) of HM17321

    Time to reach maximum observed plasma concentration following single and multiple subcutaneous doses.

    Time frame: Up to Day 29 (Part A); Up to Day 113 (Part B)

  3. Area Under Plasma Concentration-Time Curve (AUC) of HM17321

    Area under the plasma concentration-time curve from time zero to the last measurable concentration following single and multiple subcutaneous doses.

    Time frame: Up to Day 29 (Part A); Up to Day 113 (Part B)

Other outcomes

  1. Change from Baseline in Body Weight

    Body weight measured in kilograms.

    Time frame: Up to Day 29 (Part A); Up to Day 113 (Part B)

07

Study locations

1 of 1 sites recruiting
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
    Recruiting
    • Leela Vrishabhendra · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 16 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 22, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219589
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Nov 6, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 4, 2026

Study contacts

Jimin Han
Contact
jimin.han@hanmi.co.kr
+82-2-410-9838

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion